Grape Seed Extract FS

In one study, 287 patients diagnosed with asymptomatic carotid plaques or abnormal plaque free carotid intima-media thickness (CIMT) were randomly assigned to a GSE group (n = 146) or control group (n = 141). As anticipated, after treatment, GSE resulted in significant reduction in MMCIMT progression, while MMCIMT and plaque score were stable and even increased with the control group. The number of plaques and unstable plaques also decreased after treatment of GSE. Furthermore, the carotid plaque can disappear after treatment with GSE. The incidence rate for transitory ischemic attack (TIA), arterial revascularization procedure, and hospital readmission for unstable angina in GSE group was significantly lower compared with the control group 1. * These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Another study related to cardiovascular health investigated effects of a grape extract supplement containing resveratrol on stable patients with coronary artery disease (CAD) treated according to currently accepted guidelines for secondary prevention of cardiovascular disease. In a tripleblind, randomized, placebo-controlled, one-year follow-up, 3-arm pilot clinical trial, 75 stable-CAD patients received 350 mg/day of placebo, resveratrol-containing grape extract (grape phenolics plus 8 mg resveratrol) or conventional grape extract lacking resveratrol during 6 months, and a double dose for the following 6 months. Changes in circulating inflammatory and fibrinolytic biomarkers were analyzed. Moreover, the transcriptional profiling of inflammatory genes in peripheral blood mononuclear cells (PBMCs) was explored using microarrays and functional gene expression analysis. After 1 year, in contrast to the placebo and conventional grape extract groups, the resveratrol-containing grape extract group showed an increase of the anti-inflammatory serum adiponectin and a decrease of the thrombogenic plasminogen activator inhibitor type 1. In addition, 6 key inflammation-related transcription factors were predicted to be significantly activated or inhibited, with 27 extracellular-space acting genes involved in inflammation, cell migration and T-cell interaction signals presenting downregulation in PBMCs. No adverse effects were detected in relation to the study products. Chronic daily consumption of a resveratrolcontaining grape nutraceutical could exert cardiovascular benefits in stableCAD patients treated according to current evidence-based standards, by increasing serum adiponectin, preventing PAI-1 increase and inhibiting atherothrombotic signals in PBMCs 8.